Affects up to 1% of patients on oral anticoagulation per year, and is the most feared and devastating complication of this treatment. After such an event, it is unclear whether anticoagulant therapy should be resumed. Such a decision hinges upon the assessment of the competing risks of haematoma growth or recurrent ICH and thromboembolic events. ICH location and the risk for ischaemic cerebrovascular event seem to be the key factors that lead to risk/benefit balance of restarting anticoagulation after ICH.
The other category of intracranial hemorrhage is:
Subarachnoid hemorrhage, which all occur within the skull but outside of the brain tissue.
Anticoagulation associated intracranial hemorrhage (ICH).